Nektar Therapeutics
NASDAQ:NKTR · NASDAQ Global Select
-$1.24 today
Vol 0.81M · Avg 1.00M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:NKTR · Revenue to Net Income
Key Ratios
Analysis
$55.6M of revenue converted into -$158.1M of net income for the selected period. Gross margin is 99.2% and net margin is -313.1%, showing how much revenue survives after costs and taxes. EPS is $-8.42, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $55.2M -43.9% | $98.4M +9.2% | $90.1M -2.1% | $92.1M -9.7% | $101.9M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $0 -100.0% | $30.7M -16.3% | $36.6M +69.4% | $21.6M -13.1% | $24.9M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $55.2M -18.5% | $67.7M +26.7% | $53.5M -24.1% | $70.4M -8.6% | $77.0M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 100.0% +31.2pp | 68.8% +9.5pp | 59.3% -17.2pp | 76.5% +0.9pp | 75.6% | 9.8% | 28.9% | 38.3% |
| Research & Development | $117.3M -3.0% | $120.9M +5.9% | $114.2M -47.7% | $218.3M -45.5% | $400.3M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $68.7M -10.5% | $76.8M -0.9% | $77.4M -16.2% | $92.3M -24.8% | $122.8M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $186.0M +7.6% | $172.9M -9.4% | $190.9M -38.5% | $310.7M -40.6% | $523.1M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $1.0M -76.6% | $4.4M -43.8% | $7.8M -35.9% | $12.2M -13.8% | $14.1M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$137.0M -58.0% | -$86.7M +64.3% | -$243.1M +24.9% | -$323.9M +29.9% | -$461.8M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -248.1% -160.0pp | -88.1% +181.7pp | -269.8% +82.1pp | -351.8% +101.4pp | -453.2% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$130.8M -24.3% | -$105.2M +23.5% | -$137.4M +42.8% | -$240.2M +46.1% | -$446.1M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -236.8% -129.9pp | -106.9% +45.6pp | -152.5% +108.5pp | -261.0% +176.8pp | -437.8% | 16.6% | 24.1% | 22.0% |
| Interest Income | $10.4M -28.0% | $14.5M -23.7% | $19.0M +180.2% | $6.8M +148.4% | $2.7M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $26.2M -6.9% | $28.1M +11.0% | $25.3M -12.4% | $28.9M -38.9% | $47.3M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$33.4M -138.8% | -$14.0M +89.9% | -$138.8M -11.3% | -$124.7M -61.6% | -$77.2M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$164.2M -37.8% | -$119.2M +56.9% | -$276.3M +24.3% | -$365.0M +30.3% | -$523.3M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -297.3% -176.2pp | -121.1% +185.4pp | -306.5% +89.9pp | -396.5% +117.0pp | -513.5% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$138.0K +42.3% | -$239.0K -19.5% | -$200.0K -106.2% | $3.2M +477.2% | $557.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | -$164.1M -37.9% | -$119.0M +56.9% | -$276.1M +25.0% | -$368.2M +29.7% | -$523.8M | $4.9B | $4.8B | $4.7B |
| Net Margin | -297.1% -176.2pp | -120.9% +185.5pp | -306.3% +93.7pp | -400.0% +114.1pp | -514.0% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$10 -12.1% | -$9 +60.2% | -$22 +26.2% | -$30 +31.2% | -$43 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$10 -12.1% | -$9 +60.2% | -$22 +26.2% | -$30 +31.2% | -$43 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $16.9M +23.0% | $13.7M +8.2% | $12.7M +1.5% | $12.5M +2.1% | $12.2M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $16.9M +23.0% | $13.7M +8.2% | $12.7M +1.5% | $12.5M +2.1% | $12.2M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Relay Therapeutics, Inc.
NASDAQ:RLAY
$2.79B
Enliven Therapeutics, Inc.
NASDAQ:ELVN
$2.72B
Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
$1.68B
Atai Beckley Inc.
NASDAQ:ATAI
$1.47B
Inhibrx Biosciences, Inc.
NASDAQ:INBX
$1.34B
Immatics N.V.
NASDAQ:IMTX
$1.30B
Amylyx Pharmaceuticals, Inc.
NASDAQ:AMLX
$1.28B
Xencor, Inc.
NASDAQ:XNCR
$930.11M
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
$880.42M
Sana Biotechnology, Inc.
NASDAQ:SANA
$850.18M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does NKTR generate?
Nektar Therapeutics (NKTR) reported $55.23M of revenue in fiscal 2025.
Is NKTR profitable?
Nektar Therapeutics (NKTR) reported -$164,076,000.00 of net income, with a net margin of -297.1%.
Explore More
Continue the stock analysis
Jump to another research area for this company.